UNSPSC 41116161: Primary and secondary antibodies for multiple methodology immunostaining detection application

Primary and secondary antibodies that are are available for universal detection by multiple methodologies including but not limited to fluorescent microscopy, western blot, immunopreciptiation, chromatin immunoprecipitation, flow cytometry, immunohistochemistry, immunocytochemistry, and electron microscopy

UNSPSC 41116161 Primary and secondary antibodies for multiple methodology immunostaining detection application is a Commodity code that does not reflect the actual work state and local governments are buying under this designation. The recent state and local contract opportunities tagged to this code involve HIV and Syphilis testing reagents, forensic laboratory services, clinical diagnostic blood chemistry testing, offender drug-screening specimen collection and testing, and pool maintenance—none of which require or specify primary and secondary antibodies for immunostaining applications. The code taxonomy appears misaligned with current procurement activity; the opportunities represent testing kit procurement (Abbott HIV/Syphilis reagents, rapid HIV test kits), laboratory testing services (forensic analysis, drug screening), and facility maintenance work that fall outside antibody-based immunostaining methodology entirely.

State and local procurement activity under this code shows no relevant recent opportunities. Illinois Department of Public Health, the City of Austin, Collin County Community Supervision and Corrections Department, the Texas Department of Criminal Justice, University of Houston, and Collier County have all posted solicitations in the past four months tagged to code 41116161, but the work being solicited—rapid HIV test kits (Austin IFB, July 17, 2026 response date), Abbott HIV/Syphilis reagents (Illinois IDPH emergency procurements, May 2026), offender drug-screening services (Collin County RFP 2026-327, July 23, 2026 response date), and forensic analysis (TDCJ RFP 696-IG-26-P034, May 13, 2026 response date)—does not align with the code's stated scope. The geographic spread includes Texas, Illinois, and Florida, but the mismatch between code definition and actual procurement content suggests this code is not an appropriate or useful target for business development planning related to primary or secondary antibodies.